Stella Martomo
Senior Director, Translational Sciences EvolveImmune Therapeutics, Inc.
Seminars
Tuesday 23rd June 2026
Revolutionizing Bench to Bedside Transitions by Optimizing a Comprehensive Translational Package to Accelerate Clinical Entry
11:00 am
Join this workshop to bridge the critical gap between preclinical promise and clinical reality, where the focus shifts from molecular potency to the power of a translational data package
- Discussing ideal assays for bankable safety data beyond TCRs, such as cytokine release assays and tissue models
- Evaluating the translational impact of Fc-silencing or Fcengineering on systemic inflammation and half-life in a nonanimal context
- Discussing the current gap in translational models for ICANS/ neurotoxicity and whether specialized neuro models are ready for IND inclusion
- Deep diving into how TCE developers are harnessing the modified MABEL approach to avoid ‘sub-therapeutic’ dose escalation and save cohorts
- Discussing how unexpected clinical outcomes should trigger new in vitro or ex vivo studies
Wednesday 24th June 2026
Advancing the EVOLVE Platform with Integrated CD2 Costimulation to Enhance the Depth of T-Cell Engager Responses & Prevent Early Therapeutic Exhaustion
2:30 pm
- T‑cell engagers have shown positive clinical outcomes across multiple indications, including solid tumors, but currently approved molecules do not provide a direct co‑stimulatory signal
- The EVOLVE platform integrates CD2 co‑stimulation into CD3 multispecifics to enhance T‑cell activation, durability, and functional fitness
- An overview of the EVOLVE multispecific platform and highlight key design features that enable improved T‑cell engagement
